{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:08:05Z","timestamp":1788815285573,"version":"build-2803163510"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["2025-54786"],"award-info":[{"award-number":["2025-54786"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118319","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:52:50Z","timestamp":1785995570000},"page":"118319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Targeting USP7 in sarcomas: opportunities and challenges"],"prefix":"10.1016","volume":"253","author":[{"given":"Sara","family":"Franzese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-2562","authenticated-orcid":false,"given":"Giuliana","family":"Cassinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118319_b0005","unstructured":"WHO Classification of Tumors Editorial Board. Soft Tissue and Bone Tumours 5th ed., vol. 3, IARC Press, Lyon, 2020."},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0010","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911131","article-title":"Sarcoma treatment in the era of molecular medicine","volume":"12","author":"Gr\u00fcnewald","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2026.118319_b0015","doi-asserted-by":"crossref","unstructured":"E. Cesarman, B. Damania, S.E. Krown, J. Martin, M. Bower, D. Whitby, Kaposi sarcoma, Nat. Rev. Dis. Primers. 5(1) (2019) 9. doi: 10.1038\/s41572-019-0060-9.","DOI":"10.1038\/s41572-019-0060-9"},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0020","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41392-021-00647-8","article-title":"Molecular mechanisms underpinning sarcomas and implications for current and future therapy","volume":"6","author":"Damerell","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0025","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cancers17050889","article-title":"Systemic treatment in soft tissue sarcomas: are we making a difference?","volume":"17","author":"Paudel","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118319_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105252","article-title":"Advances in osteosarcoma research: pathogenesis and emerging therapeutic strategies","volume":"222","author":"Yan","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188613","article-title":"Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas","volume":"1876","author":"Fordham","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11864-022-00947-3","article-title":"Proteomic and metabolomic profiling in soft tissue sarcomas","volume":"23","author":"Chadha","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers17010010","article-title":"Novel therapeutics in soft tissue sarcoma","volume":"17","author":"Mavroeidis","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118319_b0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2017.06.006","article-title":"Therapeutic applications of histone deacetylase inhibitors in sarcoma","volume":"59","author":"Tang","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2026.118319_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114944","article-title":"Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas","volume":"198","author":"Lanzi","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0060","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers13071513","article-title":"Dysregulation of the ubiquitin proteasome system in human malignancies: a window for therapeutic intervention","volume":"13","author":"Fhu","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41580-021-00448-5","article-title":"Ubiquitin ligases: guardians of mammalian development","volume":"23","author":"Cruz Walma","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0070","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.tcb.2022.02.005","article-title":"Quality control of protein complex assembly by the ubiquitin-proteasome system","volume":"32","author":"Pla-Prats","year":"2022","journal-title":"Trends Cell Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2023.194979","article-title":"Ubiquitination and deubiquitination: Implications on cancer therapy","volume":"1866","author":"Dagar","year":"2023","journal-title":"Biochim. Biophys. Acta, Gene Regul. Mech."},{"issue":"22","key":"10.1016\/j.bcp.2026.118319_b0080","doi-asserted-by":"crossref","first-page":"16346","DOI":"10.3390\/ijms242216346","article-title":"PROTAC-based protein degradation as a promising strategy for targeted therapy in sarcomas","volume":"24","author":"Mancarella","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0085","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/CCO.0000000000001146","article-title":"MDM2 inhibitors in sarcomas: results and next steps","volume":"37","author":"Tortorelli","year":"2025","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0090","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/ph19030476","article-title":"The MDM2-p53 Axis in osteosarcoma: current understanding of regulatory mechanisms and targeted therapeutic strategies","volume":"19","author":"Deng","year":"2026","journal-title":"Pharmaceuticals"},{"issue":"6467","key":"10.1016\/j.bcp.2026.118319_b0095","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.aax3769","article-title":"Cellular quality control by the ubiquitin-proteasome system and autophagy","volume":"366","author":"Pohl","year":"2019","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0100","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin-proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch. Pharm. Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41580-025-00870-z","article-title":"Degrons: defining the rules of protein degradation","volume":"26","author":"Zhang","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0110","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tibs.2025.07.009","article-title":"E3 ubiquitin ligases in signaling, disease, and therapeutics","volume":"50","author":"Ebadi","year":"2025","journal-title":"Trends Biochem. Sci"},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0115","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1002\/ctm2.1204","article-title":"The roles of E3 ubiquitin ligases in cancer progression and targeted therapy","volume":"13","author":"Sampson","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"32","key":"10.1016\/j.bcp.2026.118319_b0120","doi-asserted-by":"crossref","first-page":"E4639","DOI":"10.1073\/pnas.1608644113","article-title":"Numerous proteins with unique characteristics are degraded by the 26S proteasome following monoubiquitination","volume":"113","author":"Braten","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118319_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117872","article-title":"Therapeutic targeting of ubiquitin-specific protease 7 (USP7): Mechanistic insights, dysregulation, and advances in drug discovery","volume":"296","author":"El-Hamaky","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2026.118319_b0130","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/bioinformatics\/bty1067","article-title":"UbiHub: a data hub for the explorers of ubiquitination pathways","volume":"35","author":"Liu","year":"2019","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0135","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/diagnostics11030496","article-title":"MDM2 amplified sarcomas: a literature review","volume":"11","author":"Sciot","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0140","first-page":"e2159","article-title":"RNF135 promotes human osteosarcoma cell growth and inhibits apoptosis by upregulating the PI3K\/AKT pathway","volume":"7","author":"Chen","year":"2024","journal-title":"Cancer Rep. (Hoboken)."},{"key":"10.1016\/j.bcp.2026.118319_b0145","article-title":"RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis","volume":"6(43)","author":"S\u00e1nchez-Molina","year":"2020","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101077","article-title":"Deubiquitinating enzymes (DUBs): regulation, homeostasis, and oxidative stress response","volume":"297","author":"Snyder","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0155","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/biom15020240","article-title":"Ubiquitin-specific protease inhibitors for cancer therapy: recent advances and future prospects","volume":"15","author":"Bakkar","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2026.118319_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114797","article-title":"Ubiquitin-specific proteases as therapeutic targets in paediatric primary bone tumours?","volume":"194","author":"Mullard","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118319_b0165","article-title":"The role of ubiquitination in osteosarcoma development and therapies","volume":"14(7)","author":"Mao","year":"2024","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002703","article-title":"The ubiquitin\/proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cells","volume":"8","author":"Greene","year":"2012","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0175","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/emboj\/16.3.566","article-title":"A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein","volume":"16","author":"Everett","year":"1997","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188903","article-title":"USP7 - a crucial regulator of cancer hallmarks","volume":"1878","author":"Saha","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"20","key":"10.1016\/j.bcp.2026.118319_b0185","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.3390\/molecules30204038","article-title":"USP7 at the crossroads of ubiquitin signaling, cell cycle, and tumorigenesis","volume":"30","author":"Lusardi","year":"2025","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0190","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(02)01199-6","article-title":"Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde","volume":"111","author":"Hu","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118319_b0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fcell.2020.00717","article-title":"USP7 is a master regulator of genome stability","volume":"8","author":"Valles","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0200","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14728222.2023.2266571","article-title":"Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment","volume":"27","author":"Carreira","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"issue":"17","key":"10.1016\/j.bcp.2026.118319_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2025.169298","article-title":"The C-terminal tail of ubiquitin-specific protease 7 facilitates ubiquitin release and ensures efficient catalytic turnover","volume":"437","author":"Korchak","year":"2025","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118319_b0210","article-title":"Emerging roles of USP7 in tumor immune evasion, metabolic reprogramming, and therapeutic resistance","volume":"17","author":"Liu","year":"2026","journal-title":"Front. Immunol."},{"issue":"22","key":"10.1016\/j.bcp.2026.118319_b0215","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.jmb.2017.05.028","article-title":"Regulation of USP7: a high incidence of E3 complexes","volume":"429","author":"Kim","year":"2017","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0220","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41418-018-0144-1","article-title":"A complex of the ubiquitin ligase TRIM32 and the deubiquitinase USP7 balances the level of c-Myc ubiquitination and thereby determines neural stem cell fate specification","volume":"26","author":"Nicklas","year":"2019","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0225","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbrc.2010.08.082","article-title":"Regulation of the Polycomb protein RING1B ubiquitination by USP7","volume":"400","author":"de Bie","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2026.118319_b0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-018-0012-y","article-title":"Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases","volume":"3","author":"Bhattacharya","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"issue":"Pt 2","key":"10.1016\/j.bcp.2026.118319_b0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.semcancer.2020.03.008","article-title":"Dissenting degradation: deubiquitinases in cell cycle and cancer","volume":"67","author":"Bonacci","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0240","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1371\/journal.pbio.0040027","article-title":"Structural basis of competitive recognition of p53 and MDM2 by HAUSP\/USP7: implications for the regulation of the p53-MDM2 pathway","volume":"4","author":"Hu","year":"2006","journal-title":"PLoS Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0245","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1097-2765(04)00157-1","article-title":"A dynamic role of HAUSP in the p53-Mdm2 pathway","volume":"13","author":"Li","year":"2004","journal-title":"Mol. Cell"},{"issue":"6881","key":"10.1016\/j.bcp.2026.118319_b0250","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature737","article-title":"Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization","volume":"416","author":"Li","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118319_b0255","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.18632\/oncotarget.1989","article-title":"Usp7 protects genomic stability by regulating Bub3","volume":"5","author":"Giovinazzi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118319_b0260","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nsmb.3185","article-title":"USP7 is a SUMO deubiquitinase essential for DNA replication","volume":"23","author":"Lecona","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118319_b0265","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1038\/onc.2017.21","article-title":"DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer","volume":"36","author":"Hern\u00e1ndez-P\u00e9rez","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114366","article-title":"The phosphorylation-deubiquitination positive feedback loop of the CHK2-USP7 axis stabilizes p53 under oxidative stress","volume":"43","author":"Liu","year":"2024","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.bcp.2026.118319_b0275","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2422262122","article-title":"TAOK1 promotes filament formation in HR repair through phosphorylating USP7","volume":"122","author":"Zhu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0280","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.molcel.2012.01.002","article-title":"PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes","volume":"45","author":"Gao","year":"2012","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0285","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1128\/MCB.01197-14","article-title":"USP7 cooperates with SCML2 to regulate the activity of PRC1","volume":"35","author":"Lecona","year":"2015","journal-title":"Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0290","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/nar\/gkab209","article-title":"Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis","volume":"49","author":"Su","year":"2021","journal-title":"Nucl. Acids Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0295","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2019-0338","article-title":"USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells","volume":"43","author":"Lee","year":"2020","journal-title":"Genet. Mol. Biol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118319_b0300","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/onc.2009.427","article-title":"Inactivation of HAUSP in vivo modulates p53 function","volume":"29","author":"Kon","year":"2010","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0305","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41436-019-0433-1","article-title":"Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies","volume":"21","author":"Fountain","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcp.2026.118319_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.970649","article-title":"Expansion of the mutation spectrum and phenotype of USP7-related neurodevelopmental disorder","volume":"15","author":"Zheng","year":"2022","journal-title":"Front. Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0315","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cge.14480","article-title":"Hao-Fountain syndrome: 32 novel patients reveal new insights into the clinical spectrum","volume":"105","author":"Wimmer","year":"2024","journal-title":"Clin. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188992","article-title":"Current and future directions of USP7 interactome in cancer study","volume":"1878","author":"Park","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118319_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.784672","article-title":"Ubiquitin-specific peptidase 7: a novel deubiquitinase that regulates protein homeostasis and cancers","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jmcb\/mjw049","article-title":"Modulation of the p53\/MDM2 interplay by HAUSP inhibitors","volume":"9","author":"Tavana","year":"2017","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118319_b0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.dnarep.2019.02.005","article-title":"USP7: structure, substrate specificity, and inhibition","volume":"76","author":"Pozhidaeva","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.bcp.2026.118319_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153621","article-title":"Prognostic role of USP7 expression in cancer patients: a systematic review and meta-analysis","volume":"227","author":"Kisa\u00ef","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bcp.2026.118319_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112107","article-title":"Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors","volume":"191","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0350","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nchembio.2557","article-title":"Drug development: allosteric inhibitors hit USP7 hard","volume":"14","author":"Zhang","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118319_b0355","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1038\/ncomms5763","article-title":"Screening of DUB activity and specificity by MALDI-TOF mass spectrometry","volume":"5","author":"Ritorto","year":"2014","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0360","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nchembio.2528","article-title":"Discovery and characterization of highly potent and selective allosteric USP7 inhibitors","volume":"14","author":"Gavory","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0365","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0370","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/adt.2010.0317","article-title":"Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format","volume":"9","author":"Tian","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0375","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.chembiol.2011.08.018","article-title":"Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes","volume":"18","author":"Altun","year":"2011","journal-title":"Chem. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118319_b0380","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1038\/cddis.2013.400","article-title":"USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis","volume":"4","author":"Fan","year":"2013","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.bcp.2026.118319_b0385","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.chembiol.2017.09.004","article-title":"USP7-specific inhibitors target and modify the enzyme's active site via distinct chemical mechanisms","volume":"24","author":"Pozhidaeva","year":"2017","journal-title":"Cell Chem. Biol."},{"issue":"7677","key":"10.1016\/j.bcp.2026.118319_b0390","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature24006","article-title":"USP7 small-molecule inhibitors interfere with ubiquitin binding","volume":"550","author":"Kategaya","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bcp.2026.118319_b0395","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2017.09.003","article-title":"Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7","volume":"24","author":"Lamberto","year":"2017","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0400","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1038\/s41598-020-62076-x","article-title":"Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism","volume":"10","author":"Schauer","year":"2020","journal-title":"Sci. Rep."},{"issue":"7677","key":"10.1016\/j.bcp.2026.118319_b0405","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"issue":"63","key":"10.1016\/j.bcp.2026.118319_b0410","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1039\/D2CC02094G","article-title":"Targeting the deubiquitinase USP7 for degradation with PROTACs","volume":"58","author":"Murgai","year":"2022","journal-title":"Chem. Commun. (Camb)"},{"issue":"33","key":"10.1016\/j.bcp.2026.118319_b0415","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202204395","article-title":"Discovery of a potent and selective degrader for USP7","volume":"61","author":"Pei","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0420","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1084\/jem.20171066","article-title":"Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma","volume":"215","author":"Stolte","year":"2018","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0425","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000808","article-title":"The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies","volume":"4","author":"Boulay","year":"2020","journal-title":"Life Sci. Alliance"},{"issue":"12","key":"10.1016\/j.bcp.2026.118319_b0430","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1074\/jbc.M115.710632","article-title":"Identification of Kaposi Sarcoma Herpesvirus (KSHV) vIRF1 protein as a novel interaction partner of human deubiquitinase USP7","volume":"291","author":"Chavoshi","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118319_b0435","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.1005727","article-title":"Highlights in USP7 inhibitors for cancer treatment","volume":"10","author":"Oliveira","year":"2022","journal-title":"Front. Chem."},{"issue":"22","key":"10.1016\/j.bcp.2026.118319_b0440","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.3390\/cancers14225539","article-title":"USP7 inhibitors in cancer immunotherapy: current status and perspective","volume":"14","author":"Korenev","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0445","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432234","article-title":"Immunotherapy in sarcoma: current data and promising strategies","volume":"44","author":"Wood","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.bcp.2026.118319_b0450","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/152382","article-title":"At-risk populations for osteosarcoma: the syndromes and beyond","volume":"2012","author":"Calvert","year":"2012","journal-title":"Sarcoma"},{"issue":"17","key":"10.1016\/j.bcp.2026.118319_b0455","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.3390\/cancers13174284","article-title":"TP53 in biology and treatment of osteosarcoma","volume":"13","author":"Synoradzki","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118319_b0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2016.10.017","article-title":"Molecular genetics of osteosarcoma","volume":"102","author":"Rickel","year":"2017","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0465","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/biom14070791","article-title":"The role of ubiquitination in osteosarcoma development and therapies","volume":"14","author":"Mao","year":"2024","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.bcp.2026.118319_b0470","doi-asserted-by":"crossref","first-page":"880","DOI":"10.20892\/j.issn.2095-3941.2024.0231","article-title":"Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies","volume":"21","author":"Shen","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bcp.2026.118319_b0475","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/gcc.20761","article-title":"Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma","volume":"49","author":"Mejia-Guerrero","year":"2010","journal-title":"Genes Chromosom. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0480","first-page":"543","article-title":"Ubiquitin\u2011specific protease 7 promotes osteosarcoma cell metastasis by inducing epithelial\u2011mesenchymal transition","volume":"41","author":"Zeng","year":"2019","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0485","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41420-024-01893-9","article-title":"mTORC1 accelerates osteosarcoma progression via m6A-dependent stabilization of USP7 mRNA","volume":"10","author":"Yang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bcp.2026.118319_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111819","article-title":"USP7 promotes the malignant progression of osteosarcoma through the KPNA2\/PKLR axis","volume":"132","author":"Wang","year":"2025","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0495","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncb2142","article-title":"TSPYL5 suppresses p53 levels and function by physical interaction with USP7","volume":"13","author":"Epping","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"17","key":"10.1016\/j.bcp.2026.118319_b0500","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jnci\/86.17.1297","article-title":"MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status","volume":"86","author":"Fl\u00f8renes","year":"1994","journal-title":"J. Natl Cancer Inst."},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0505","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1073\/pnas.0507493103","article-title":"Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy","volume":"103","author":"Tovar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0510","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.molcel.2019.05.027","article-title":"TSPYL5 depletion induces specific death of ALT Cells through USP7-dependent proteasomal degradation of POT1","volume":"75","author":"Episkopou","year":"2019","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0515","article-title":"Specific death of ALT cells through TSPYL5 depletion","volume":"6","author":"Claude","year":"2019","journal-title":"Mol. Cell. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0520","doi-asserted-by":"crossref","DOI":"10.1002\/pro.70116","article-title":"Structural insights into the interaction between testis-specific Y-encoded-like protein 5 and ubiquitin-specific protease 7","volume":"34","author":"Ancia","year":"2025","journal-title":"Protein Sci."},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0525","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899692","article-title":"USP7 limits CDK1 activity throughout the cell cycle","volume":"40","author":"Galarreta","year":"2021","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0530","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra2028910","article-title":"Ewing's Sarcoma","volume":"384","author":"Riggi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0535","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing Sarcoma","volume":"4","author":"Gr\u00fcnewald","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.bcp.2026.118319_b0540","article-title":"Recurrent and refractory Ewing sarcoma phase I\/II trials: current perspective from the euro-ewing consortium","volume":"9","author":"Juan Ribelles","year":"2025","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0545","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10555-019-09839-9","article-title":"Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies","volume":"38","author":"Knott","year":"2019","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0550","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CCO.0000000000001048","article-title":"Emerging therapies in Ewing sarcoma","volume":"36","author":"Strauss","year":"2024","journal-title":"Curr. Opin. Oncol."},{"issue":"31","key":"10.1016\/j.bcp.2026.118319_b0555","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.24.00020","article-title":"Open-label, multicenter, phase I\/II, first-in-human trial of TK216: a first-generation EWS::FLI1 fusion protein antagonist in Ewing sarcoma","volume":"42","author":"Meyers","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2026.118319_b0560","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1158\/1078-0432.CCR-22-0696","article-title":"Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed ewing sarcoma: results of a basket phase II study","volume":"28","author":"Subbiah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118319_b0565","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/746939","article-title":"Targeting the p53 pathway in Ewing sarcoma","volume":"2011","author":"Neilsen","year":"2011","journal-title":"Sarcoma"},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0570","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/path.4378","article-title":"Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53","volume":"233","author":"van der Ent","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2026.118319_b0575","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pharmthera.2019.06.010","article-title":"TP53 in bone and soft tissue sarcomas","volume":"202","author":"Thoenen","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0580","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2013.11.002","article-title":"Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer","volume":"344","author":"Van Maerken","year":"2014","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0585","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101618","article-title":"Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies","volume":"8","author":"Blay","year":"2023","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189215","article-title":"Advances of SS18-SSX fusion gene in synovial sarcoma: emerging novel functions and therapeutic potentials","volume":"1879","author":"Ren","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0600","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11864-018-0525-1","article-title":"Systemic treatment for adults with synovial sarcoma","volume":"19","author":"Desar","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.bcp.2026.118319_b0605","article-title":"Synovial sarcoma: a complex disease with multifaceted signaling and epigenetic landscapes","volume":"22(12)","author":"El Beaino","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"38","key":"10.1016\/j.bcp.2026.118319_b0610","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1038\/s41388-025-03547-1","article-title":"Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatment","volume":"44","author":"Wang","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0615","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cell.2013.02.036","article-title":"Reversible disruption of mSWI\/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma","volume":"153","author":"Kadoch","year":"2013","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bcp.2026.118319_b0620","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1158\/2159-8290.CD-20-1219","article-title":"A role for SMARCB1 in synovial sarcomagenesis reveals that SS18-SSX induces canonical BAF destruction","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.bcp.2026.118319_b0625","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/j.1349-7006.2012.02370.x","article-title":"SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group","volume":"103","author":"Kawaguchi","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118319_b0630","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fonc.2019.01078","article-title":"Epigenetic targets in synovial sarcoma: a mini-review","volume":"9","author":"Hale","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118319_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115727","article-title":"Targeting EZH2 in SMARCB1-deficient sarcomas: advances and opportunities to potentiate the efficacy of EZH2 inhibitors","volume":"215","author":"Lanzi","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0640","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.32604\/or.2025.060573","article-title":"The SS18-SSX fusion oncoprotein: friend and foe in targeted therapy for synovial sarcoma","volume":"33","author":"Anchondo","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bcp.2026.118319_b0645","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41305","article-title":"Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma","volume":"7","author":"Brien","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2026.118319_b0650","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.isci.2019.02.008","article-title":"HDAC2 regulates site-specific acetylation of MDM2 and its ubiquitination signaling in tumor suppression","volume":"13","author":"Patel","year":"2019","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0655","article-title":"HDAC2 links ubiquitination to tumor suppression in synovial sarcoma","volume":"8","author":"Cooley","year":"2021","journal-title":"Mol. Cell. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0660","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.2017.75.1941","article-title":"Synovial sarcoma: current concepts and future perspectives","volume":"36","author":"Stacchiotti","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0665","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1074\/jbc.M116.749564","article-title":"UbE2E1\/UBCH6 is a critical in Vivo E2 for the PRC1-catalyzed ubiquitination of H2A at Lys-119","volume":"292","author":"Wheaton","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118319_b0670","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2340\/1651-226X.2024.40537","article-title":"Classic Kaposi sarcoma: diagnostics, treatment modalities, and genetic implications - a review of the literature","volume":"63","author":"Batash","year":"2024","journal-title":"Acta Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0675","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70565","article-title":"Oncogenic mechanisms of Kaposi's sarcoma-associated herpesvirus on cell metabolism and cell transformation","volume":"97","author":"Wan","year":"2025","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0680","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12967-023-04130-6","article-title":"Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis","volume":"21","author":"Openshaw","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118319_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110384","article-title":"Mouse models of Kaposi sarcoma-associated herpesvirus (KSHV)","volume":"603","author":"Shifflett","year":"2025","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0690","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/JVI.80.2.697-709.2006","article-title":"Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function","volume":"80","author":"Si","year":"2006","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.bcp.2026.118319_b0695","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1128\/JVI.02353-08","article-title":"Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway","volume":"83","author":"Lee","year":"2009","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0700","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/1354750X.2010.525664","article-title":"MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in african and Caucasian patients","volume":"16","author":"Tornesello","year":"2011","journal-title":"Biomarkers"},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0705","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/abbs\/gmu133","article-title":"Regulation of cellular innate antiviral signaling by ubiquitin modification","volume":"47","author":"Lin","year":"2015","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.bcp.2026.118319_b0710","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fmicb.2012.00066","article-title":"The ubiquitin system and Kaposi's sarcoma-associated herpesvirus","volume":"3","author":"Ashizawa","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bcp.2026.118319_b0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198076","article-title":"USP7 manipulation by viral proteins","volume":"286","author":"Bojagora","year":"2020","journal-title":"Virus Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.118319_b0720","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/nsmb.2142","article-title":"Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein","volume":"18","author":"Lee","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0725","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00255-24","article-title":"Biologically significant interaction of human herpesvirus 8 viral interferon regulatory factor 4 with ubiquitin-specific protease 7","volume":"98","author":"Yang","year":"2024","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0730","doi-asserted-by":"crossref","first-page":"e02003","DOI":"10.1128\/JVI.02003-17","article-title":"Human herpesvirus 8 interferon regulatory factors 1 and 3 mediate replication and latency activities via interactions with USP7 deubiquitinase","volume":"92","author":"Xiang","year":"2018","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0735","doi-asserted-by":"crossref","first-page":"e01553","DOI":"10.1128\/JVI.01553-19","article-title":"USP7-dependent regulation of TRAF activation and signaling by a viral interferon regulatory factor homologue","volume":"94","author":"Xiang","year":"2020","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118319_b0740","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1128\/JVI.06840-11","article-title":"The ubiquitin-specific protease USP7 modulates the replication of Kaposi's sarcoma-associated herpesvirus latent episomal DNA","volume":"86","author":"J\u00e4ger","year":"2012","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118319_b0745","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1128\/JVI.02925-14","article-title":"A survey of the interactome of Kaposi's sarcoma-associated herpesvirus ORF45 revealed its binding to viral ORF33 and cellular USP7, resulting in stabilization of ORF33 that is required for production of progeny viruses","volume":"89","author":"Gillen","year":"2015","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011943","article-title":"Non-canonical regulation of the reactivation of an oncogenic herpesvirus by the OTUD4-USP7 deubiquitinases","volume":"20","author":"Wang","year":"2024","journal-title":"PLoS Pathog."},{"issue":"10","key":"10.1016\/j.bcp.2026.118319_b0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005918","article-title":"Regulation of the abundance of kaposi's sarcoma-associated herpesvirus ORF50 protein by oncoprotein MDM2","volume":"12","author":"Chang","year":"2016","journal-title":"PLoS Pathog."},{"issue":"10","key":"10.1016\/j.bcp.2026.118319_b0760","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1042\/BCJ20160304","article-title":"USP7 deubiquitinase controls HIV-1 production by stabilizing Tat protein","volume":"474","author":"Ali","year":"2017","journal-title":"Biochem. J"},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0765","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/v9080222","article-title":"Inhibitors of deubiquitinating enzymes block HIV-1 replication and augment the presentation of gag-derived MHC-I epitopes","volume":"9","author":"Setz","year":"2017","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0770","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.drudis.2020.10.028","article-title":"The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy","volume":"26","author":"Nininahazwe","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"39","key":"10.1016\/j.bcp.2026.118319_b0775","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2510252122","article-title":"Functional spectrum of USP7 pathogenic variants in Hao-Fountain syndrome: Insights into the enzyme's activity, stability, and allosteric modulation","volume":"122","author":"Korchak","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"42","key":"10.1016\/j.bcp.2026.118319_b0780","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2510496122","article-title":"Small-molecule allosteric activator of ubiquitin-specific protease 7 (USP7)","volume":"122","author":"Jaen Maisonet","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"21","key":"10.1016\/j.bcp.2026.118319_b0785","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426632122","article-title":"Activation dynamics of ubiquitin-specific protease 7","volume":"122","author":"Valles","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0790","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13046-024-03056-1","article-title":"The deubiquitinase USP7 and E3 ligase TRIM21 regulate vasculogenic mimicry and malignant progression of RMS by balancing SNAI2 homeostasis","volume":"43","author":"Zhang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0795","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s004280050418","article-title":"Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas","volume":"435","author":"Schneider-Stock","year":"1999","journal-title":"Virchows Arch."},{"issue":"9","key":"10.1016\/j.bcp.2026.118319_b0800","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/modpathol.3880180","article-title":"Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma","volume":"13","author":"Oda","year":"2000","journal-title":"Mod. Pathol."},{"issue":"33","key":"10.1016\/j.bcp.2026.118319_b0805","doi-asserted-by":"crossref","first-page":"34680","DOI":"10.18632\/oncotarget.5786","article-title":"Next generation sequencing in synovial sarcoma reveals novel gene mutations","volume":"6","author":"Vlenterie","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0810","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/1541-7786.MCR-07-0176","article-title":"The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability","volume":"6","author":"D'Arcy","year":"2008","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0815","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4161\/cc.19756","article-title":"Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells","volume":"11","author":"Ye","year":"2012","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0820","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ccell.2018.01.018","article-title":"The SS18-SSX oncoprotein Hijacks KDM2B-PRC1.1 to drive synovial sarcoma","volume":"33","author":"Banito","year":"2018","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.bcp.2026.118319_b0825","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1038\/emboj.2010.129","article-title":"Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor","volume":"29","author":"Maertens","year":"2010","journal-title":"EMBO J."},{"issue":"13","key":"10.1016\/j.bcp.2026.118319_b0830","doi-asserted-by":"crossref","DOI":"10.1172\/JCI190855","article-title":"DNA demethylating agents suppress preclinical models of synovial sarcoma","volume":"135","author":"Hasegawa","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0835","doi-asserted-by":"crossref","first-page":"15833","DOI":"10.1038\/s41598-018-34197-x","article-title":"Identification and characterization of USP7 targets in cancer cells","volume":"8","author":"Georges","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118319_b0840","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ceb.2019.02.008","article-title":"Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease","volume":"58","author":"Rawat","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0845","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/jcb.22998","article-title":"Usp7 and Uhrf1 control ubiquitination and stability of the maintenance DNA methyltransferase Dnmt1","volume":"112","author":"Qin","year":"2011","journal-title":"J. Cell. Biochem."},{"issue":"17\u201318","key":"10.1016\/j.bcp.2026.118319_b0850","first-page":"1016","article-title":"USP7 substrates identified by proteomics analysis reveal the specificity of USP7","volume":"36","author":"Nie","year":"2022","journal-title":"Genes Dev."},{"issue":"35","key":"10.1016\/j.bcp.2026.118319_b0855","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1038\/onc.2014.384","article-title":"Polycomb-dependent repression of the potassium channel-encoding gene KCNA5 promotes cancer cell survival under conditions of stress","volume":"34","author":"Ryland","year":"2015","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.bcp.2026.118319_b0860","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1158\/0008-5472.CAN-07-6152","article-title":"BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression","volume":"68","author":"Douglas","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118319_b0865","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.876602","article-title":"Novel targeting of DNA methyltransferase activity inhibits ewing sarcoma cell proliferation and enhances tumor cell sensitivity to DNA damaging drugs by activating the DNA damage response","volume":"13","author":"Cristalli","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b0870","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/15592294.2020.1805678","article-title":"Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein","volume":"16","author":"Theisen","year":"2021","journal-title":"Epigenetics"},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0875","first-page":"1202","article-title":"Epigenetic modifications in osteosarcoma: mechanisms and therapeutic strategies","volume":"15","author":"Katsianou","year":"2025","journal-title":"Life (Basel)."},{"key":"10.1016\/j.bcp.2026.118319_b0880","article-title":"USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities","volume":"9(20)","author":"Liu","year":"2023","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.bcp.2026.118319_b0885","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2013.05.018","article-title":"Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity","volume":"39","author":"van Loosdregt;","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.118319_b0890","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ebiom.2016.10.018","article-title":"Ubiquitin-specific protease-7 inhibition impairs Tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity","volume":"13","author":"Wang","year":"2016","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0895","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s13287-018-0991-1","article-title":"Induction of CD4+CD25+FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation","volume":"9","author":"Khosravi","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.bcp.2026.118319_b0900","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","article-title":"The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation","volume":"42","author":"DuPage","year":"2015","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b0905","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"issue":"24","key":"10.1016\/j.bcp.2026.118319_b0910","doi-asserted-by":"crossref","first-page":"16622","DOI":"10.1021\/acs.jmedchem.2c01444","article-title":"Discovery of orally bioavailable N-benzylpiperidinol derivatives as potent and selective USP7 inhibitors with in vivo antitumor immunity activity against colon cancer","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118319_b0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115732","article-title":"Discovery of o-aminodiphenyl-based USP7 inhibitor for immune activation and antitumor response in colorectal cancer","volume":"167","author":"Jia","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118319_b0920","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41401-024-01263-2","article-title":"Inhibition of USP7 enhances CD8(+) T cell activity in liver cancer by suppressing PRDM1-mediated FGL1 upregulation","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118319_b0925","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8852221","article-title":"Cells of the innate and adaptive immune systems in Kaposi's sarcoma","volume":"2020","author":"Ngalamika","year":"2020","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.bcp.2026.118319_b0930","article-title":"Targeting ubiquitin-specific protease 7 (USP7) in cancer: a new insight to overcome drug resistance","volume":"12","author":"Lu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0935","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/ijms25052768","article-title":"ER Stress-Activated HSF1 governs cancer cell resistance to USP7 inhibitor-based chemotherapy through the PERK pathway","volume":"25","author":"Lim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0940","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1038\/s41467-025-56981-w","article-title":"USP7 V517F mutation as a mechanism of inhibitor resistance","volume":"16","author":"Miao","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0945","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-020-0143-9","article-title":"Inhibition of USP14 and UCH37 deubiquitinating activity by b-AP15 as a potential therapy for tumors with p53 deficiency","volume":"5","author":"Ma","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"15","key":"10.1016\/j.bcp.2026.118319_b0950","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1158\/0008-5472.CAN-16-1040","article-title":"Proteasome addiction defined in ewing sarcoma is effectively targeted by a novel class of 19s proteasome inhibitors","volume":"76","author":"Shukla","year":"2016","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.118319_b0955","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3390\/cells10092268","article-title":"Overexpression of the ubiquitin specific proteases USP43, USP41, USP27x and USP6 in osteosarcoma cell lines: inhibition of osteosarcoma tumor growth and lung metastasis development by the usp antagonist PR619","volume":"10","author":"Lavaud","year":"2021","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bcp.2026.118319_b0960","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.7150\/ijbs.82081","article-title":"Deubiquitinase USP13 regulates glycolytic reprogramming and progression in osteosarcoma by stabilizing METTL3\/m6A\/ATG5 axis","volume":"19","author":"Wang","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0965","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12967-023-04126-2","article-title":"Ubiquitin specific peptidase 37 and PCNA interaction promotes osteosarcoma pathogenesis by modulating replication fork progression","volume":"21","author":"Chauhan","year":"2023","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b0970","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40659-017-0121-z","article-title":"Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro","volume":"50","author":"Gan","year":"2017","journal-title":"Biol. Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118319_b0975","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3727\/096504016X14772395226335","article-title":"Downregulation of ubiquitin-specific protease 22 inhibits proliferation, invasion, and epithelial-mesenchymal transition in osteosarcoma cells","volume":"25","author":"Zhang","year":"2017","journal-title":"Oncol. Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0980","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2011.07.040","article-title":"USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma","volume":"146","author":"Williams","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.118319_b0985","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.3892\/ijo.2016.3752","article-title":"Gene silencing of USP1 by lentivirus effectively inhibits proliferation and invasion of human osteosarcoma cells","volume":"49","author":"Liu","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b0990","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.7150\/ijbs.65428","article-title":"USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ","volume":"18","author":"Yuan","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.118319_b0995","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13577-025-01221-y","article-title":"LncRNA OLMALINC promotes osteosarcoma progression through USP1-mediated autophagy suppression","volume":"38","author":"Li","year":"2025","journal-title":"Hum. Cell"},{"issue":"11","key":"10.1016\/j.bcp.2026.118319_b1000","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/1541-7786.MCR-23-0323","article-title":"USP1 expression driven by EWS:FLI1 transcription factor stabilizes survivin and mitigates replication stress in ewing sarcoma","volume":"21","author":"Mallard","year":"2023","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b1005","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41598-018-37264-5","article-title":"USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth","volume":"9","author":"Gierisch","year":"2019","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.bcp.2026.118319_b1010","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1038\/sj.onc.1208506","article-title":"Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes","volume":"24","author":"Oliveira","year":"2005","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2026.118319_b1015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jcp-2023-208896","article-title":"Unravelling the USP6 gene: an update","volume":"76","author":"Cordier","year":"2023","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118319_b1020","first-page":"733","article-title":"A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells","volume":"7","author":"Nakamura","year":"1992","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2026.118319_b1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2013.03.005","article-title":"USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis","volume":"45","author":"Oliveira","year":"2014","journal-title":"Hum. Pathol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b1030","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-20-1458","article-title":"Ubiquitin-specific protease 6 functions as a tumor suppressor in ewing sarcoma through immune activation","volume":"81","author":"Henrich","year":"2021","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.118319_b1035","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/2767-9764.CRC-22-0505","article-title":"Natural killer cell activation by ubiquitin-specific protease 6 mediates tumor suppression in ewing sarcoma","volume":"3","author":"Jain","year":"2023","journal-title":"Cancer Res. Commun."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:17:52Z","timestamp":1788812272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":207,"alternative-id":["S0006295226006581"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118319","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting USP7 in sarcomas: opportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118319"}}